Sage Therapeutics Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced new data from the LANDSCAPE clinical program evaluating the efficacy and safety of zuranolone for the treatment of major depressive disorder (MDD) presented at the American College of Neuropsychopharmacology (ACNP) Congress taking place December 5-8 in San Juan, Puerto Rico. Data from the SHORELINE and WATERFALL Studies in the LANDSCAPE clinical program further the understand

SummerHaven Investment Management LLC purchased a new stake in Sage Therapeutics, Inc. (NASDAQ:SAGE) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 17,315 shares of the biopharmaceutical companys stock, valued at approximately $767,000. A number of other institutional investors also recently added to []

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranol

Sage Therapeutics Inc (NASDAQ: SAGE ) and Biogen Inc (NASDAQ: BIIB ) have announced 12-month data for the cohort of patients (n=199) who received zuranolone 50 mg once for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study. Related: Sage Therapeutics - Biogen''s Zuranolone Tops Placebo In Reducing Depressive Symptoms . The data showed that zuranolone was generally well-tolerated, with no new safety findings or trends identified in the long-term safety Full story available on Benzinga.com

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir The Food and Drug Adminis

Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have announced 12-month data for the cohort of patients (n=199) who received zuranolone 50 mg once for 14-days as their initial

Even a good year for stocks has its share of high-flyers that have turned into losers — or buying opportunities.

Sage Therapeutics Inc (SAGE) shares closed today at 0.5% above its 52 week low of $38.35, giving the company a market cap of $2B. The stock is currently down 54.5% year-to-date, down 48.0% over the past 12 months, and down 21.9% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 34.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 302.7% The company's stock price performance over the past 12 months lags the peer average by 382.4% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -62.2% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with

Sage Therapeutics Inc. (NASDAQ:SAGE) shares, rose in value on Friday, 11/26/21, with the stock price down by -1.72% to the previous days close as strong demand from buyers drove the stock to $39.32. Actively observing the price movement in the last trading, the stock closed the session at $40.01, falling within a range of $38.35 Sage Therapeutics Inc. (NASDAQ: SAGE): Whats Next In 2021? Read More »